Search clinical trials for: LVGN3616 LVGN6051 Bevacizumab Cyclophosphamide

Total 86 results

M.D. Anderson Cancer Center
Lyvgen Biopharma Holdings Limited

Recruiting

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

Gastric Cancer | Metastatic Uveal Melanoma | Metastatic Head and Neck Carcinoma | Metastatic Hepatocellular Carcinoma | Metastatic Ovarian Carcinoma | Metastatic Soft Tissue Sarcoma | Metastatic Esophageal | Metastatic HPV Related Solid Tumors

United States
Sanofi

Completed

Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer

Breast Cancer

United States
Swiss Group for Clinical Cancer Research

Completed

Metronomic Therapy in Metastatic Breast Cancer.

Breast Cancer

Switzerland
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; North Central...

Active, not recruiting

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Breast Adenocarcinoma

United States, Peru, South Africa
University of California, San Francisco
Novartis

Completed

Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

Unspecified Adult Solid Tumor

United States
Cancer Trials Ireland

Completed

TC Avastin. ICORG 08-10, V6

Breast Cancer

Ireland, Denmark
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; University of Colorado, Denver; Genentech, Inc.; Sidney... and other collaborators

Completed

Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

Sarcoma | Neuroblastoma

United States, Canada
University of Alabama at Birmingham
Genentech, Inc.; Ortho Biotech, Inc.

Completed

Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin

Invasive Breast Cancer

United States
Hospital Universitario Madrid Sanchinarro

Unknown

Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer

Breast Cancer

Spain
German Breast Group
AGO Study Group

Completed

Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (GeparQuinto)

Breast Cancer

Germany
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lymphoma | Leukemia

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer

United States
Epitopoietic Research Corporation
University of California, Irvine

Active, not recruiting

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Glioblastoma | Gliosarcoma

United States
Roswell Park Cancer Institute

Completed

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
Translational Oncology Research International
Genentech, Inc.

Completed

Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)

Breast Cancer

Canada, United States, Ireland
Cancer Institute and Hospital, Chinese Academy...
Beijing Huanxing Cancer Hospital

Recruiting

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

Metastatic Breast Cancer

China
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Genentech... and other collaborators

Completed

Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer

Breast Cancer

United States
NSABP Foundation Inc
Genentech, Inc.; US Oncology Research

Completed

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Breast Cancer

United States, Ireland
UNICANCER

Completed

Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients (Beverly1)

Breast Cancer

France
Azienda Ospedaliero, Universitaria Pisana

Completed

Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer (MOMA)

Metastatic Colorectal Cancer

Italy
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Phase II Bevacizumab + Tax In Advanced Breast Cancer

Breast Cancer

United States
University of Tennessee Cancer Institute
Genentech, Inc.; Celgene Corporation; National Comprehensive Cancer Network

Unknown

Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

Breast Cancer

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Genentech, Inc.

Completed

Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer

Breast Cancer

United States
West German Study Group
Sanofi; Roche Pharma AG

Terminated

Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)

Breast Cancer

Germany
NSABP Foundation Inc
National Cancer Institute (NCI)

Unknown

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

Breast Cancer

United States, Canada, Puerto Rico
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Breast Cancer

United States, Puerto Rico
New Approaches to Neuroblastoma Therapy Consortium
National Cancer Institute (NCI)

Completed

N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

Neuroblastoma

United States, Canada
Auxilio Mutuo Cancer Center

Unknown

"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" (NACprotocol)

Infiltrating Duct and Lobular Carcinoma In Situ | Invasive Lobular Breast Carcinoma | Inflammatory Breast Carcinoma

Puerto Rico
Cambridge University Hospitals NHS Foundation Trust

Unknown

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer

Breast Cancer | Perioperative/Postoperative Complications | Cardiac Toxicity

United Kingdom
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Unknown

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

Lymphoma

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Genentech, Inc.; Brigham and Women's Hospital

Completed

Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
National Cancer Institute (NCI)

Completed

Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma

Ewing Sarcoma of Bone | Peripheral Primitive Neuroectodermal Tumor | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Extraosseous Ewing Sarcoma

United States
Abramson Cancer Center of the University of Pennsylvania

Terminated

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | Ovarian Carcinoma

United States
National Cancer Institute (NCI)

Completed

Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Recurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Previously Treated Childhood Rhabdomyosarcoma | Adult Rhabdomyosarcoma | Childhood Alveolar Rhabdomyosarcoma | Childhood Pleomorphic Rhabdomyosarcoma | Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features

United States, Canada, Australia, New Zealand
ImmunityBio, Inc.

Withdrawn

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Triple Negative Breast Cancer
ImmunityBio, Inc.

Withdrawn

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Non Hodgkin Lymphoma
University of Nebraska
National Cancer Institute (NCI)

Terminated

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2-negative Breast Cancer

United States
University of Arkansas
Genentech, Inc.

Completed

Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer

Breast Cancer

United States
Hellenic Oncology Research Group

Terminated

Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer

Breast Cancer

Greece
Celgene

Completed

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Breast Cancer

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma

United States, Puerto Rico
M.D. Anderson Cancer Center

Recruiting

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Ovarian Cancer

United States
St. Jude Children's Research Hospital

Completed

Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia

Leukemia | Refractory Solid Tumors

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

Lymphoma

United States
ImmunityBio, Inc.

Unknown

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Pancreatic Cancer

United States
University of Birmingham
Roche Pharma AG; Cancer Research UK; Imagine for Margo; EUSA Pharma, Inc.

Active, not recruiting

Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children (BEACON)

Neuroblastoma

France, Austria, Belgium, Denmark, Ireland, Italy, Spain, Switzerland, United Kingdom, Netherlands
St. Jude Children's Research Hospital
University of Florida; University of Tennessee; Nemours Children's Clinic

Active, not recruiting

Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Desmoplastic Small Round Cell Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Ewing Sarcoma of Bone or Soft Tissue | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

United States

Search clinical trials for: LVGN3616 LVGN6051 Bevacizumab Cyclophosphamide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations